Experiences and management of uncertainty following treatment for prostate cancer
. (Source: Health, Risk and Society)
Source: Health, Risk and Society - April 26, 2024 Category: International Medicine & Public Health Authors: Richard GreenSchool of Health Sciences, University of Surrey, Manor Park, UK Source Type: research
Patterns of Failure After Prostate-Only Radiotherapy in High-Risk Prostate Cancer: Implications for Refining Pelvic Nodal Contouring Guidelines
CONCLUSION: Pelvic failures accounted for a major proportion of recurrences after prostate-only radiotherapy, with the caudal most nodal recurrence being 20 mm cranial to the top of pubic symphysis. This could have implications in defining the caudal border of contouring recommendations.PMID:38664178 | DOI:10.1016/j.clon.2024.04.001 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 25, 2024 Category: Cancer & Oncology Authors: M Singh P Maitre R Mody V Murthy Source Type: research
Comprehensive analysis of macrophage-related genes in prostate cancer by integrated analysis of single-cell and bulk RNA sequencing
Aging (Albany NY). 2024 Apr 24;16. doi: 10.18632/aging.205727. Online ahead of print.ABSTRACTMacrophages, as essential components of the tumor immune microenvironment (TIME), could promote growth and invasion in many cancers. However, the role of macrophages in tumor microenvironment (TME) and immunotherapy in PCa is largely unexplored at present. Here, we investigated the roles of macrophage-related genes in molecular stratification, prognosis, TME, and immunotherapeutic response in PCa. Public databases provided single-cell RNA sequencing (scRNA-seq) and bulk RNAseq data. Using the Seurat R package, scRNA-seq data was pr...
Source: Aging - April 25, 2024 Category: Biomedical Science Authors: Jili Zhang Zhihao Li Zhenlin Chen Wenzhen Shi Yue Xu Zhangcheng Huang Zequn Lin Ruiling Dou Shaoshan Lin Xin Jiang Mengqiang Li Shaoqin Jiang Source Type: research
Patterns of Failure After Prostate-Only Radiotherapy in High-Risk Prostate Cancer: Implications for Refining Pelvic Nodal Contouring Guidelines
CONCLUSION: Pelvic failures accounted for a major proportion of recurrences after prostate-only radiotherapy, with the caudal most nodal recurrence being 20 mm cranial to the top of pubic symphysis. This could have implications in defining the caudal border of contouring recommendations.PMID:38664178 | DOI:10.1016/j.clon.2024.04.001 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 25, 2024 Category: Cancer & Oncology Authors: M Singh P Maitre R Mody V Murthy Source Type: research
Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial
CONCLUSIONS AND CLINICAL IMPLICATIONS: This single-center, single-arm, phase 2 trial demonstrated that PDT in oligoprogressive mCRPC resulted in median NEST-FS of 17 mo without any early or late grade ≥3 toxicity.PATIENT SUMMARY: For patients with metastatic prostate cancer no longer responding to hormone therapy, we investigated radiotherapy targeted at progressive cancer lesions while continuing their ongoing systemic treatment. The results show that this targeted therapy had very low toxicity and delayed the need to start a new line of systemic treatment by 17 months.PMID:38664137 | DOI:10.1016/j.euo.2024.04.003 (Source: Cancer Control)
Source: Cancer Control - April 25, 2024 Category: Cancer & Oncology Authors: Kato Rans Steven Joniau Charlien Berghen Karolien Goffin Herlinde Dumez Karin Haustermans Gert De Meerleer Source Type: research
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
Conclusion: PSMA PET/CT upstaged 17% of patients, which allowed for more accurate radiotherapy planning. Unfortunately, this trial closed early before completion of target enrollment (54/316, 17%) and was underpowered to assess the effect of PSMA PET/CT on progression-free survival.PMID:38664019 | DOI:10.2967/jnumed.123.267004 (Source: Cancer Control)
Source: Cancer Control - April 25, 2024 Category: Cancer & Oncology Authors: John Nikitas Ethan Lam Kiara Adame Booker Wolfgang P Fendler Matthias Eiber Boris Hadaschik Ken Herrmann Nader Hirmas Helena Lanzafame Martin Stuschke Johannes Czernin Michael L Steinberg Nicholas G Nickols Amar U Kishan Jeremie Calais Source Type: research
Comprehensive analysis of macrophage-related genes in prostate cancer by integrated analysis of single-cell and bulk RNA sequencing
Aging (Albany NY). 2024 Apr 24;16. doi: 10.18632/aging.205727. Online ahead of print.ABSTRACTMacrophages, as essential components of the tumor immune microenvironment (TIME), could promote growth and invasion in many cancers. However, the role of macrophages in tumor microenvironment (TME) and immunotherapy in PCa is largely unexplored at present. Here, we investigated the roles of macrophage-related genes in molecular stratification, prognosis, TME, and immunotherapeutic response in PCa. Public databases provided single-cell RNA sequencing (scRNA-seq) and bulk RNAseq data. Using the Seurat R package, scRNA-seq data was pr...
Source: Aging - April 25, 2024 Category: Biomedical Science Authors: Jili Zhang Zhihao Li Zhenlin Chen Wenzhen Shi Yue Xu Zhangcheng Huang Zequn Lin Ruiling Dou Shaoshan Lin Xin Jiang Mengqiang Li Shaoqin Jiang Source Type: research
Cotrimoxazole and targeted antibiotic prophylaxis for transrectal prostate biopsy: a single-center study
ConclusionsUsing cotrimoxazole as PAP for TRPB in cases without multiresistant gram-negatives in pre-interventional urine cultures or rectal swabs seems feasible and practical. (Source: World Journal of Urology)
Source: World Journal of Urology - April 25, 2024 Category: Urology & Nephrology Source Type: research
Treatment Response Imaging in Prostate Cancer
This study will review the different criteria for imaging treatment response on conventional and advanced molecular imaging for different therapies, and the future perspective in posttherapy imaging. (Source: PET Clinics)
Source: PET Clinics - April 25, 2024 Category: Radiology Authors: Mina Swiha, Andrei Gafita, Andrew Nguyen, Louise Emmett Source Type: research
Cardiovascular risk in ADT recipients: does the type of ADT matter?
Prostate Cancer and Prostatic Diseases, Published online: 25 April 2024; doi:10.1038/s41391-024-00832-0Cardiovascular risk in ADT recipients: does the type of ADT matter? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 25, 2024 Category: Urology & Nephrology Authors: Jehonathan H. Pinthus Wilhelmina C. M. Duivenvoorden Source Type: research
Cancers, Vol. 16, Pages 1650: Clinical Management of Intraductal Carcinoma of the Prostate
©rat
Intraductal carcinoma of the prostate (IDC-P) has emerged as a distinct entity with significant clinical implications in prostate cancer (PCa) management. Despite historically being considered an extension of invasive PCa, IDC-P shows unique biological characteristics that challenge traditional diagnostic and therapeutic settings. This review explores the clinical management of IDC-P. While the diagnosis of IDC-P relies on specific morphological criteria, its detection remains challenging due to inter-observer variability. Emerging evidence underscores the association of IDC-P with aggressive disease and poor clin...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Gabriel Wasinger Olivier Cussenot Eva Comp érat Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1653: A Metastatic Cancer Expression Generator (MetGen): A Generative Contrastive Learning Framework for Metastatic Cancer Generation
i Huang
Despite significant advances in tumor biology and clinical therapeutics, metastasis remains the primary cause of cancer-related deaths. While RNA-seq technology has been used extensively to study metastatic cancer characteristics, challenges persist in acquiring adequate transcriptomic data. To overcome this challenge, we propose MetGen, a generative contrastive learning tool based on a deep learning model. MetGen generates synthetic metastatic cancer expression profiles using primary cancer and normal tissue expression data. Our results demonstrate that MetGen generates comparable samples to actual metastatic ...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Zhentao Liu Yu-Chiao Chiu Yidong Chen Yufei Huang Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1647: Inter- and Intra-Patient Repeatability of Radiomic Features from Multiparametric Whole-Body MRI in Patients with Metastatic Prostate Cancer
Conclusions: Pyradiomics texture features of mCRPC bone metastases varied greatly in inter- and intra-patient repeatability. Several features demonstrated good repeatability, allowing for further exploration as diagnostic parameters in mCRPC bone disease. (Source: Cancers)
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Ricardo Donners Antonio Candito Mihaela Rata Adam Sharp Christina Messiou Dow-Mu Koh Nina Tunariu Matthew D. Blackledge Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1643: Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective
Francesco Ceci
In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, PSMA was studied as a therapeutic agent targeted with various isotopes. In 2021, results from the VISION trial led to the Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) and set the ba...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Francesco Mattana Lorenzo Muraglia Antonio Barone Marzia Colandrea Yasmina Saker Diffalah Silvia Provera Alfio Severino Cascio Emanuela Omodeo Sal è Francesco Ceci Tags: Review Source Type: research
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer
ConclusionIn a large, multicentre study evaluating 600 patients with newly diagnosed intermediate and high-risk PCa, we showed that PSMA PET/CT may have a value in local tumour staging when pathological tumour stage in the radical prostatectomy specimen was used as the reference standard. The intra-observer and interobserver variability of assessment of tumour extent on PSMA PET/CT was moderate to substantial. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 24, 2024 Category: Nuclear Medicine Source Type: research
